整理 | GLP1减重宝典内容团队 2025年6月20日 —— RNA药物研发公司Wave Life Sciences Ltd.（纳斯达克代码：WVE）在2025年6月20日至23日于芝加哥召开的《美 国糖尿病协会第85届年度科学会议（ADA Scientific Sessions）》上，公开其候选药物WVE-007的最新临床前研究成果。 WVE-007是一种经过GalNAc修饰的小干扰RNA（siRNA），靶向沉默INHBE mRNA——该靶点因其在人类遗传学中与肥胖密切相关 而受到高度关注。研究显示，WVE-007可通过下调Activin E蛋白，显著减少脂肪量而不损害肌肉质量，并能抑制促炎性巨噬细胞在内 脏脂肪组织中的聚集，从而有助于改善代谢性炎症环境。数据表明，INHBE-siRNA干预可能降低2型糖尿病（T2D）和冠心病（CAD） 等代谢疾病的风险。 研究要点： 单次INHBE-siRNA给药可显著下调INHBE mRNA及其产物Activin E蛋白，后者在肥胖状态下会抑制脂肪分解。肝脏INHBE mRNA水 平与血清Activin E浓度呈高度相关。 单次WVE-007处理所导致的体重下降幅度与 ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insig ...

Wave Life Sciences (WVE) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Welcome everyone to twenty twenty five Jefferies Global Healthcare Conference. My name is Roger Song, one of the seniors covers MidCap Biotech at Jefferies. It's my pleasure to have the fireside chat with our next presenting company from Wave Life Sciences and CEO, Paul. Speaker1 Thank you, Roger. We're excited to be here. We have a lot to talk about going into the second half. Speaker0 Yes. We have a few minutes to cover your pipel ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be a ...

Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave's robust RNA medicines pipeline CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive te ...

Wave Life Sciences (WVE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.41%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.17, delivering a surprise of 200%.Over the last four quarters, the ...

Wave Life Sciences (WVE) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Kate Rausch - VP - Investor Relations & Corporate AffairsPaul Bolno - President, CEO & DirectorErik Ingelsson - Chief Scientific OfficerKyle Moran - CFOJenny Gonzalez-Armenta - Equity Research AssociateYun Zhong - SVP - Equity ResearchSalim Syed - Managing Director, Equity ResearchCatherine Novack - Director - Healthcare Equity ResearchCha Cha Yang - Senior Associate, Biotech Equity ResearchAnanda Ghosh - VP - Equit ...

Wave Life Sciences (WVE) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the Wave Life Sciences First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded and webcasted. After today's presentation, there'll be an opportunity to ask questions. To ask question, you may press and one on your touch tone telephone. To withdraw your question, may press and 2. I now turn the cal ...

Wave Life Sciences Corporate Presentation May 8, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth opportunities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other juris ...